Richard S M, Bianchi N O, Bianchi M S, Peltomäki P, Lothe R A, Pavicic W
Instituto Multidisciplinario de Biología Celular, La Plata, Argentina.
Mutat Res. 2004 Oct 4;554(1-2):45-51. doi: 10.1016/j.mrfmmm.2004.03.001.
Seventy-six percent of testicular cancers of origin in Finns have been reported to exhibit AZF deletions. We analyze here 40 testicular tumor cases from Norway and Argentina and we found that AZF deletions occur also in non-Finnish cases but at significantly lower frequency (25%) than in Finland testicular tumor cases. This frequency difference can be attributed to the condition of genetic isolate of the Finnish population and the subsequent prevalence in this ethnic group of genetic factors involved in the origin of AZF deletions associated with malignancies. The finding of a correlation between AZF deletions and a given Y haplogroup would indicate the existence of Y lineages carrying AZF deletion-enhancing gene or genes. This possibility was explored using a set of Y-DNA-markers allowing the identification of Y lineages occurring at high frequency in Finns. We characterized the Y haplogroups in 32 normal Finn males (control group) and 17 cases of testicular cancer in Finns with and without AZF deletions. We found no association between Y lineages and AZF microdeletions, nor between AZF microdeletions and a Y microdeletion (DYS7C) exhibiting high prevalence (>50%) in Finns. The lack of correlation between AZF deletions and Y haplogroups indicates that the origin of these deletions is independent from the Y chromosome genetic background. No AZF deletions were found in familial cases of testicular tumors; hence, hereditary factors inducing the appearance of testicular malignancies in certain genealogies apparently do not increase the susceptibility to AZF deficiencies. AZF deletions are de novo events occurring in prezygotic or in post-zygotic stages. We propose that most AZF deletions associated with testicular tumors are due to post-zygotic Y microdeletions, while most cases of deletions associated with infertility are due to deletions occurring in the germ cell line of proband fathers.
据报道,芬兰人原发性睾丸癌中有76%存在AZF缺失。我们在此分析了来自挪威和阿根廷的40例睾丸肿瘤病例,发现非芬兰病例中也存在AZF缺失,但频率(25%)显著低于芬兰睾丸肿瘤病例。这种频率差异可归因于芬兰人群的遗传隔离状况以及该族群中与恶性肿瘤相关的AZF缺失起源所涉及的遗传因素的后续流行情况。AZF缺失与特定Y单倍群之间存在相关性这一发现将表明存在携带AZF缺失增强基因的Y谱系。我们使用一组Y-DNA标记来探索这种可能性,这些标记能够识别在芬兰人中高频出现的Y谱系。我们对32名正常芬兰男性(对照组)以及17例有或无AZF缺失的芬兰睾丸癌病例的Y单倍群进行了特征分析。我们发现Y谱系与AZF微缺失之间没有关联,AZF微缺失与在芬兰人中高流行率(>50%)的Y微缺失(DYS7C)之间也没有关联。AZF缺失与Y单倍群之间缺乏相关性表明这些缺失的起源独立于Y染色体遗传背景。在睾丸肿瘤的家族病例中未发现AZF缺失;因此,在某些家系中诱发睾丸恶性肿瘤出现的遗传因素显然不会增加对AZF缺陷的易感性。AZF缺失是在合子前或合子后阶段发生的新生事件。我们提出,与睾丸肿瘤相关的大多数AZF缺失是由于合子后Y微缺失,而与不育相关的大多数缺失病例是由于先证者父亲生殖细胞系中发生的缺失。